Want to see SE:SANION full AI Analyst Report?
Saniona AB (SANION) AI Stock Analysis
Saniona AB
(Nasdaq OMX AB:SANION)
Strong financial performance from the turnaround to high-margin profitability and positive cash flows is the primary driver. Mixed technical signals with short-term support but longer-term downtrend and attractive low P/E valuation provide additional support.
Saniona AB (SANION) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 1.54B
- Dividend Yield
- ―
- Average Volume (3M)
- 436.47K
- Price to Earnings (P/E)
- 8.3
- Beta (1Y)
- 0.39
- Revenue Growth
- 24.98%
- EPS Growth
- -31.44%
- Country
- Sweden
- Employees
- 44
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Saniona AB Business Overview & Revenue Model
Company Description
Saniona AB (publ), founded in 2011 and based in Glostrup, Denmark, is a biopharmaceutical company focused on rare diseases. It specializes in discovering, developing, and commercializing treatments specifically targeting central nervous system disord...
Saniona AB Financial Statement Overview
Summary
Strong profitability with high margins over 51%, debt-free balance sheet, and robust positive cash flows of 187 million in TTM reflect solid recovery and operational efficiency.
Income Statement
85Very PositiveBalance Sheet
88Very PositiveCash Flow
90Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 424.56M | 434.40M | 334.67M | 16.84M | 15.28M | 10.48M |
| Gross Profit | 263.78M | 286.37M | 329.58M | 11.78M | 10.81M | 5.85M |
| EBITDA | 209.32M | 314.46M | 251.90M | -68.28M | -198.41M | -398.86M |
| Net Income | 183.53M | 284.67M | 188.71M | -95.81M | -245.36M | -410.90M |
Balance Sheet | ||||||
| Total Assets | 600.98M | 679.74M | 339.73M | 64.14M | 153.70M | 440.25M |
| Cash, Cash Equivalents and Short-Term Investments | 486.31M | 580.82M | 303.26M | 30.96M | 111.71M | 356.86M |
| Total Debt | 0 | 0 | 10.50M | 71.41M | 81.52M | 99.77M |
| Total Liabilities | 52.77M | 44.58M | 107.92M | 86.08M | 100.99M | 158.25M |
| Stockholders Equity | 548.22M | 635.16M | 231.82M | -21.94M | 52.71M | 282.00M |
Cash Flow | ||||||
| Free Cash Flow | 187.39M | 200.30M | 249.07M | -85.66M | -282.52M | -346.52M |
| Operating Cash Flow | 193.65M | 273.86M | 249.20M | -85.53M | -281.54M | -345.04M |
| Investing Cash Flow | -13.52M | -77.62M | -124.00K | -129.00K | 6.84M | 43.16M |
| Financing Cash Flow | -722.26K | 108.19M | 23.25M | -7.97M | -20.52M | 50.60M |
Saniona AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SANION, the sentiment is Neutral. The current price of 11.13 is above the 20-day moving average (MA) of 10.24, above the 50-day MA of 10.47, and below the 200-day MA of 14.72, indicating a neutral trend. The MACD of 0.29 indicates Negative momentum. The RSI at 57.73 is Neutral, neither overbought nor oversold. The STOCH value of 70.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:SANION.
Saniona AB Peers Comparison
Overall Rating
SE:CAMX80Outperform- SE:SANION77Outperform
SE:BIOA.B65Neutral
SE:HNSA55Neutral
SE:ALZCUR48.1Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| SE:CAMX | 80Outperform | SEK 40.76B | 59.09 | 15.54% | ― | <0.01% | -6.75% |
| SE:SANION | 77Outperform | SEK 1.54B | 8.30 | 29.71% | ― | 24.98% | -31.44% |
| SE:BIOA.B | 65Neutral | SEK 28.15B | 266.55 | 5.18% | 0.68% | -46.09% | -90.13% |
| SE:HNSA | 55Neutral | SEK 4.00B | -5.00 | ― | ― | -3.57% | 8.84% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| SE:ALZCUR | 48Neutral | SEK 882.54M | 42.87 | 65.99% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:SANION | Saniona AB | 11.13 | -4.73 | -29.82% | |
| SE:HNSA | Hansa Biopharma | 39.34 | 8.34 | 26.90% | |
| SE:MVIR | Medivir | 1.55 | 1.02 | 191.35% | |
| SE:CAMX | Camurus AB | 673.00 | 46.00 | 7.34% | |
| SE:ALZCUR | AlzeCure Pharma AB | 6.40 | 4.51 | 238.45% | |
| SE:BIOA.B | BioArctic AB Class B | 317.20 | 36.66 | 13.07% |
Saniona AB Corporate Events
Saniona Files IND for Rapid-Acting Depression Drug SAN2465
Saniona has filed an Investigational New Drug application with the U.S. Food and Drug Administration for SAN2465, an experimental therapy aimed at major depressive disorder, with a Phase 1 trial in healthy volunteers planned by year-end pending regul...
Saniona advances SAN2465 as oral rapid-acting antidepressant with new preclinical data
Saniona has reported new preclinical data showing that its investigational drug SAN2465 significantly enhances hippocampal synaptic plasticity, a mechanism closely linked to learning, memory and antidepressant action. The compound, a GABA-A α5 n...
Saniona maps out busy 2026 conference schedule to showcase neurology pipeline
Saniona plans an active presence at key investor, life science and scientific conferences through the remainder of 2026, including events in Stockholm, Lund, Cologne, Kolding, Rome, Washington, Vilnius and Denver. By presenting its programs and strat...
Saniona Calls Extraordinary Meeting to Seek Fresh Issuance Mandate
Saniona AB has called an extraordinary shareholders’ meeting for 2 November 2026 in Malmö to address key corporate governance and financing matters. Shareholders must be registered with Euroclear Sweden AB by 23 October and submit notice o...
Saniona readies IND filing for rapid-acting oral antidepressant SAN2465
Saniona has completed the toxicology and chemistry, manufacturing and controls studies for its experimental antidepressant SAN2465, securing the non-clinical and manufacturing data needed to support an Investigational New Drug application. The compan...
Saniona Narrows R&D Focus as Losses Widen but Cash Position Strengthens
Saniona reported a sharp year-on-year decline in revenue and a significantly wider operating loss for the first half of 2026, even as its cash and cash equivalents rose to SEK 486.3 million, indicating a strengthened balance sheet despite deepening l...
Saniona Schedules Q2 Investor Call for 27 August 2026
Saniona AB has invited investors to join its Q2 investor call on 27 August 2026 at 11:00 CEST, where management will present quarterly results and a broader company update. The event, hosted via Redeye with a webcast replay available on the company&#...
AstronauTx Takes Global Rights to Saniona Neurology Program as ATX0926 Moves Toward Clinic
Saniona and U.K.-based biotechnology firm AstronauTx have advanced their 2023 collaboration to a new stage, with AstronauTx exercising its option to acquire exclusive worldwide rights to a neurological disease program based on a novel ion channel tar...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 14, 2026